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Background: Pain management with conventional opioids can be challenging due to dose-
limiting adverse events (AEs), some of which may be related to the simultaneous activation
of β-arrestin (a signaling pathway associated with opioid-related AEs) and G-protein path-
ways. The investigational analgesic oliceridine is a G-protein-selective agonist at the µ-
opioid receptor with less recruitment of β-arrestin. The objective of this phase 3, open-label,
multi-center study was to evaluate the safety and tolerability, of IV oliceridine for moderate
to severe acute pain in a broad, real-world patient population, including postoperative
surgical patients and non-surgical patients with painful medical conditions.
Methods: Adult patients with a score ≥4 on 11-point NRS for pain intensity received IV
oliceridine either by bolus or PCA; multimodal analgesia was permitted. Safety was assessed
using AE reports, study discontinuations, clinical laboratory and vital sign measures.
Results: A total of 768 patients received oliceridine. The mean age (SD) was 54.1 (16.1)
years, with 32% ≥65 years of age. Most patients were female (65%) and Caucasian (78%).
Surgical patients comprised the majority of the study population (94%), most common being
orthopedic (30%), colorectal (15%) or gynecologic (15%) procedures. Multimodal analgesia
was administered to 84% of patients. Oliceridine provided a rapid reduction in NRS pain
score by 2.2 ± 2.3 at 30 mins from a score of 6.3 ± 2.1 (at baseline) which was maintained to
the end of treatment. No deaths or significant cardiorespiratory events were reported. The
incidence of AEs leading to early discontinuation and serious AEs were 2% and 3%,
respectively. Nausea (31%), constipation (11%), and vomiting (10%) were the most common
AEs. AEs were mostly of mild (37%) or moderate (25%) severity and considered possibly or
probably related to oliceridine in 33% of patients.
Conclusion: Oliceridine IV for the management of moderate to severe acute pain was
generally safe and well tolerated in the patients studied.
ClinicalTrials.gov identifier: NCT02656875.
Keywords: acute pain, analgesia, patient-controlled, clinical trial
Introduction
Conventional parenteral opioids represent an essential resource in the management
of moderate to severe pain in acute care and in the post-surgical setting.1,2 They
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have, however, a narrow therapeutic window and are asso-
ciated with dose-limiting opioid-related adverse events
(ORAEs) such as nausea, vomiting and opioid-induced
respiratory depression (OIRD).1–3 The elderly and patients
with comorbidities (e.g. obesity, sleep-apnea) may be at an
increased risk of ORAEs.1 In recent years, the use of
multimodal analgesia is recommended to minimize the
dose and duration of opioids.4,5
The efficacy and even more importantly, the safety of
conventional opioids is defined by their cellular
mechanisms.6 Agents that bind to the μ-opioid receptor
cause downstream signaling through two distinct path-
ways: G-protein and β-arrestin.6,7 Preclinical models sug-
gest that activation of the β-arrestin pathway is associated
with ORAEs, while activation of the G-protein pathway
results in analgesia.8–10 Conventional opioids have a non-
selective mechanism, activating both pathways, thus
achieving potent analgesia often at the expense of safety
and/or tolerability.9,10 Selective activation of G-protein
signaling may represent a mechanism that offers effective
analgesia with less risk of adverse events (AEs).6,7
Selective or biased opioid-receptor agonists are a new
class of medications with the potential to widen the ther-
apeutic window. Oliceridine (TRV130; Trevena Inc.,
Chesterbrook, Pennsylvania), an investigational IV opioid,
is a novel, centrally acting μ-opioid receptor agonist that is
selective (or “biased”) toward signaling through the
G-protein pathway. Oliceridine exhibits less β-arrestin
recruitment to the μ-receptor than full agonist opioids
such as morphine or fentanyl.6 In nonclinical studies,
oliceridine was associated with potent analgesic effects
while causing less gastrointestinal dysfunction and respira-
tory depression compared to morphine.6 Similarly, phase 3
randomized, controlled clinical trials suggest that olicer-
idine offers the potential for effective analgesia with
improved safety and tolerability compared to conventional
opioids.11,12
The aim of the phase 3 ATHENA study was to evaluate
the safety and effectiveness of oliceridine in patients with
moderate to severe acute pain undergoing a wide range of
surgical procedures, or with non-surgical medical condi-
tions, warranting parenteral opioids in either setting.
Materials And Methods
Study Overview
ATHENA was a phase 3, multicenter, open-label clinical
study (Clinical Trial Identifier: NCT02656875), conducted
from December 2015 to May 2017 at 41 sites in the United
States, including ambulatory surgical centers, hospital-based
outpatient and inpatient settings, and emergency depart-
ments. This study evaluated the safety and effectiveness of
oliceridine in patients with moderate to severe acute pain,
warranting the use of a parenteral opioid. In order to accu-
rately represent IVopioid use in a broad, “real world” setting,
the study was designed to be less restrictive for patient
eligibility criteria, treatment protocol requirements, patient
population, and mode of administration.
The study was approved by the Institutional Review
Board or Independent Ethics Committee at each investiga-
tional site and was conducted in compliance with the
Declaration of Helsinki and all International Conference on
Harmonization Good Clinical Practice Guidelines. All
patients provided written informed consent before participat-
ing in the study. The list of participating trial sites is provided
in the supplementary table 1 (Supplementary Table1).
Patients
Eligible patients were 18 years of age or older experien-
cing moderate to severe acute pain following surgery or
with a painful non-surgical medical condition, defined as
≥4 on an 11-point numeric rating scale (NRS), ranging
from 0 = no pain to 10 = worst pain. Baseline NRS ratings
were obtained within 30 mins prior to receiving the first
dose of oliceridine.
Exclusion criteria included (a) medical conditions that
could have confounded the effectiveness of oliceridine
(such as acute pain without a specific etiology, undiffer-
entiated acute abdominal pain, acute breakthrough pain in
palliative “end of life” care, and pain associated with
advanced cancer [somatic, visceral, or neuropathic] or
with concurrent use of chemotherapeutic or biologic
agents for the treatment of cancer), (b) participation in
another study of oliceridine, (c) American Society of
Anesthesiologists (ASA) Physical Status classification of
IV or higher, (d) Emergency Severity Index of 1,13 (e)
hypersensitivity to opioids, (f) signs of hemodynamic
instability or respiratory insufficiency, (g) any clinically
significant medical, surgical or postsurgical, psychiatric,
and/or substance abuse condition that could confound
interpretation of study outcomes, (h) clinically significant
abnormal ECG including a QT interval using Fridericia’s
correction for rate (QTcF) interval of >450 msec in males
or >470 msec in females; as well as clinically significant
abnormal laboratory values (known or obtained at screen-
ing) indicative of hepatic impairment (defined as total
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bilirubin >2×upper limit of normal [ULN], aspartate ami-
notransferase [AST] ≥1.5×ULN AND alanine aminotrans-
ferase [ALT] ≥1.5×ULN) or renal impairment (defined as
estimated glomerular filtration rate ≤29 mL/min/1.73 m2).
Treatment
After screening, enrolled patients were treated with intra-
venous (IV) oliceridine via clinician-administered bolus
dosing and/or patient-controlled analgesia (PCA). For IV
bolus dosing, a loading dose of 1 to 2 mg was adminis-
tered and a supplemental dose of 1 mg was given within
15 mins if needed. Subsequent doses of 1 to 3 mg were
administered every 1 to 3 hrs on as-needed basis (PRN).
In settings where rapid analgesia was required (eg,
emergency departments, post-anesthesia care units), load-
ing doses of 1 to 3 mg were administered and supplemen-
tal doses of 1 to 3 mg every 5 mins PRN were allowed.
Subsequent doses of 1 mg to 3 mg every 1 to 3 hrs were
used if clinically indicated.
For PCA, a loading dose of 1.5 mg and a demand dose
of 0.5 mg were administered using a 6-mins lockout inter-
val. If clinically indicated, 1 mg supplemental doses were
allowed PRN as early as 15 mins after the initial dose,
taking into consideration, the patient’s utilization of PCA
demand doses, individual patient need, and previous
response to oliceridine treatment.
The dosing limit for oliceridine was 60 mg in the first
12 hrs. In patients reaching this limit, or in patients with
pain not adequately controlled with oliceridine as deter-
mined by the treating physician, oliceridine treatment was
discontinued and conventional treatment initiated.
Treatment duration for each patient was determined by
the clinical need for parenteral opioid therapy. The max-
imal duration of oliceridine treatment was limited to 14
days. “End of treatment” was considered as the period
within 24 hrs after the last dose of oliceridine. The dura-
tion of the post-treatment follow-up period was limited to
3 days post treatment; except when serious AEs occurred,
when the patient was followed until the AE was resolved
(Supplementary Figure 1).
Prior And Concomitant Medications
Prior medications were defined as those taken within 14
days before the first dose of oliceridine and concomitant
medications were those taken after the first dose of olicer-
idine. There was no restriction on prior use of opioids and/
or non-opioid analgesics; perioperative use of local anes-
thetics, epidural and intrathecal opioids were also allowed.
Likewise, there was no restriction on prior and concomi-
tant use of anxiolytics, sedatives, and hypnotics.
Concomitant non-opioid analgesics used as part of a multi-
modal analgesic approach were permitted based on study
site clinical guidelines. Use of other parenteral and/or oral
opioids during treatment with oliceridine was not allowed;
in the event, opioids were used, oliceridine administration
was discontinued and patients managed with conventional
opioids. There were no restrictions on medications pre-
scribed to manage opioid-related AEs such as antiemetics
and laxatives.
Medication Exposure And Safety And
Tolerability Evaluation
Patient exposure to oliceridine was reported as cumulative
dose administered (i.e., total number of milligrams of
oliceridine received during the acute treatment period)
and as cumulative duration of treatment (i.e., total hours
from the first to last dose of oliceridine). For patients
receiving only a single dose, the duration of treatment
was set to “0” hours.
AEs reported are those occurring during treatment with
oliceridine and post-treatment follow-up; or any pre-existing
AEs that have worsened in severity during the treatment
phase and post-treatment follow-up. The safety and toler-
ability of oliceridine were assessed by (1) incidence of
observed or self-reported AEs, coded based on verbatim
reported terms, using the Medical Dictionary for
Regulatory Activities (MedDRA, Version 19.0), as well as,
(2) other safety and tolerability evaluations including, som-
nolence or sedation, opioid withdrawal symptoms, vital
signs, oxygen saturation by pulse oximetry, physical exam-
ination, clinical laboratory tests, and electrocardiograms
(ECG). Vital signs, physical examinations, blood chemistry
and hematology testing were conducted at baseline (i.e.,
within 24 hrs from the first oliceridine dose) and after the
last oliceridine dose was administered. The intensity of an
AE was classified as mild, moderate or severe. An AE was
considered “serious”, if in the view of the investigator it
resulted in death, a life-threatening adverse event, inpatient
hospitalization or prolongation of existing hospitalization, a
persistent or significant incapacity or substantial disruption
of the ability to conduct normal life functions.
Somnolence and sedation were assessed using the
Moline-Roberts Pharmacologic Sedation Scale (MRPSS)
within 30 mins of the first oliceridine dose and within 1 hr
from the last oliceridine dose. The MRPSS-scale includes
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6 levels of sedation ranging from “none/minimal” to “gen-
eral anesthesia.” Additional reports of somnolence and
sedation were recorded as AEs based on occurrence.14
Opioid withdrawal symptoms were assessed, by
patients, the day after the last dose of oliceridine using
the Subjective Opiate Withdrawal Scale (SOWS)
questionnaire.15 Patients rated the intensity of 16 symp-
toms on a scale of 0 (not at all) to 4 (extremely). The total
SOWS score was derived by summing the scores for each
of the 16 individual symptoms (range, 0 to 64). Total
SOWS scores were also classified by severity.16
Oxygen saturation was monitored continuously by
pulse oximetry starting within 30 mins of the first olicer-
idine dose through the treatment period and recorded
based on institutional requirements. ECGs were performed
at baseline, within 30 mins prior to the first oliceridine
dose (in surgical patients only), 60 mins after the first dose
of oliceridine, and every 24 hrs during the treatment per-
iod. Changes from baseline were recorded for heart rate,
PR interval, RR interval, QRS interval, QT interval, and
QT interval corrected for heart rate (QTcF; Fridericia).
Effectiveness Evaluation
The analgesic effectiveness of oliceridine was assessed
using the change from baseline in the 11-point NRS for
pain intensity. NRS pain scores were evaluated within 30
mins before administration of the first oliceridine dose,
and 30 mins (± 10 mins) after administration of the first
dose. After these measurements, pain scores were not
evaluated at specific time points, but were collected at
any time thereafter during the treatment period based on
each institution’s standard of care as determined by the
patient’s treating clinician.
Statistical Methods
As an observational safety study, no formal sample size
calculations were conducted. A sample size of approxi-
mately 1,000 patients was planned based on the desired
number of patient exposures. The safety analysis popula-
tion included all enrolled patients who received at least
one dose of oliceridine, while the efficacy population
included all enrolled patients who received at least one
dose of oliceridine and had at least one post-dose NRS
pain score. To estimate dose-related effects on safety and
effectiveness parameters, patients were stratified by cumu-
lative dose subgroup: ≤4 mg, >4 to 8 mg, >8 to 16 mg,
>16 to 36 mg, and >36 mg. These dose groups were
chosen based on utilization data from a previously
completed phase 2 randomized, double-blind, placebo-
controlled study with an active comparator to evaluate
the analgesic efficacy of oliceridine compared to placebo
and morphine following abdominoplasty17 with extrapola-
tion to the 2 to 3 days of exposure expected in this study.
Patients who only received oliceridine via bolus dosing
were included in the “bolus group”. Those who received at
least one dose via a PCA device were included in the
“PCA group”, even if they received additional supplemen-
tal bolus doses of oliceridine during their course of ther-
apy. Safety data were summarized using descriptive
statistics for continuous (means and standard deviation
[SD]) and categorical (number and percentage of patients)
variables. For SOWS (based on scoring on a 16-symptom
scale), if data from ≥8 symptoms were available, the
analysis was based on the mean scores of the non-missing
symptoms to calculate the total score. If data for >8
symptoms were not reported, the total score was recorded
as “missing”. NRS scores at baseline and 30 mins after the
first dose of oliceridine and change from baseline to 30
mins were tabulated by the cumulative dose group. No
formal statistical testing was performed on the effective-
ness results.
Results
Patient Disposition
Among 1,038 patients enrolled in the ATHENA study, 768
patients were treated with oliceridine and were included in
the safety and efficacy analysis populations; 698 (91%)
patients completed the study (Figure 1). More than half of
all patients enrolled were females (65%) and Caucasian
(78%) (Table 1). Patients’ mean age (SD [range]) was 54.1
(16.1 [18–89]) years: 68% were <65 years of age; 24% were
≥65 to <75; and 8%were ≥75 years of age. Almost half of all
patients (46%) had a body mass index (BMI) ≥30 kg/m2.
Of those enrolled, 94% were in surgical settings, with
orthopedic (30%), colorectal (15%) or gynecologic (15%)
procedures as the most common surgical procedures
(Figure 2). All enrolled patients had at least one comorbid
condition. The most common medical comorbidities are
shown in Figure 3.
Prior to the first dose of oliceridine, 76% of patients
received local anesthetics (eg, bupivacaine, lidocaine, ropi-
vacaine for intraoperative pain management as nerve blocks,
for local infiltration, anesthesia adjunct), 69% of patients
received non-steroidal anti-inflammatory drugs (NSAIDs)
and 48% of patients received oral opioids (Table 2).
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Overall, 84% of the patients received multimodal analge-
sic therapy concomitantly with oliceridine (Table 2). Many
analgesics used perioperatively as part of a multimodal regi-
men were continued during the treatment phase and adminis-
tered concomitantly with oliceridine. Opioids alone or in
combination with acetaminophen were used after the last
dose of oliceridine in 78% of the patients.
Exposure To Oliceridine
Oliceridine was administered by bolus dosing (exclusively)
and by PCA device (at least once) in 55% and 45% of
patients, respectively (Table 3). The median cumulative oli-
ceridine dose was 19.3 mg, ranging from 0.9 to 223.5 mg.
The median cumulative duration of oliceridine exposure was
20.3 hrs, ranging from 0 (for patients who received a single
oliceridine dose) to 142.7 hrs. The duration of oliceridine
exposure was 0 to 26.8 hrs in the cumulative dose group of
≤4 mg that also included patients receiving a single dose. The
duration increased proportionately with each increasing
cumulative dose group, with the largest exposure in the
cumulative dose group of >36 mg across a broader range of
duration from 5.8 to 142.7 hrs (6 days). Cumulative olicer-
idine dose and duration of exposure increased with patient
age. Patients ≥65 to <75 years and those ≥75 years old had
greater duration of oliceridine exposure (36.9 hrs and 38.3
hrs, respectively) than patients <65 years old (27.6 hrs).
There were no meaningful differences in the exposure to
oliceridine between the obese (BMI ≥ 30 kg/m2) and non-
obese (BMI < 30 kg/m2) patients.
Safety And Tolerability
In the overall population, 64% of patients reported at least one
AE during the study (Table 4). Most AEs were of mild (37%)
or moderate (25%) intensity. Severe AEs were reported in 2%
of patients. The proportion of AEs categorized by the intensity
of mild, moderate or severe were similar across all the cumu-
lative dose groups (Table 4). Overall, 2% of patients had AEs
leading to early discontinuation. The most frequent AEs
Enrolled Patients  
N=1,038
Screen Failures, n=270*(26.0%)
• Inclusion criteria not met, n=116 (11.2%)
• Exclusion criteria met, n=127 (12.2%)
•  Missing, n= 20 (1.9%)
•  Other, n=10 (1.0%)
Eligible Patients  
(Safety and EfficacyAnalysis
Populations)  
n=768
Patients Who Completed Study  
n=698 (90.9%)
*Patients may have failed screening for more than 1 reason.
Cumulative oliceridine dose groups,mg
≤4
n=156
>4 to 8  
n=85
>8 to 16  
n=121
>16 to 36  
n=168
>36  
n=238
Early Discontinuations, n=70 (9.1%)
• Lack of efficacy,  n=33 (4.3%)
• Adverse event, n=17 (2.2%)
• Lost to follow-up, n=6 (0.8%)
• Withdrawal by patient, n=6 (0.8%)
• Physician decision, n=3 (0.4%)
•  Other, n=3 (0.4%)
• Protocol violation, n=2 (0.3%)
Figure 1 Patient disposition during the ATHENA study.
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reportedwere nausea (31%), constipation (11%), and vomiting
(10%). The incidence of events increased with a higher cumu-
lative dose of oliceridine; the >16–36 mg and >36 mg dose
groups also had the longest duration of exposure that could
have confounded the dose–response relationship. AEs “prob-
ably” or “possibly” related to oliceridine were reported in 33%
of patients; with a low incidence of nausea (18%), vomiting
(7%), and constipation (6%). The use of concomitant medica-
tions for nausea, vomiting, and constipation increased in
patients with higher cumulative doses of oliceridine
(Supplementary Table 2). There were no differences observed
in the overall incidence of AEs with administration via bolus
(63%) or PCA (65%). Likewise, the incidence of most com-
mon AEs of nausea, vomiting and constipation did not differ
for the two routes of administration.
Serious adverse events (SAEs) were observed in 26
patients (3%) (Table 4). Most SAEs were due to complica-
tions of surgery (eg, bleeding and infection, postoperative
ileus), secondary to an underlying medical condition (eg,
endometrial cancer) or secondary to opioid therapy (eg,
nausea, bowel dysfunction, respiratory depression, hypoxia,
and syncope). All SAEs resolved or were resolving at the
time of study completion. Only 3 patients experienced SAEs
considered by the investigator as “possibly” related to olicer-
idine: post-operative ileus (1 patient), respiratory depression
with respiratory rate <8 breaths/minute within 5 hrs of receiv-
ing oliceridine (1 patient), hepatic and renal failure con-
founded by surgical-related complications (1 patient).
The incidence of AEs in obese patients (defined as
BMI≥ 30 kg/m2) was 61% (vs 64% in the overall popula-
tion). The incidence of AEs in the elderly patients (>65 to
<75 and ≥75 years old) was 61% and 66%, respectively, in
the two elderly groups vs 64% in the overall population.
Also, the incidence of AEs considered as “probably” or
“possibly” related to oliceridine was similar in the elderly
compared to the overall population (30% in the age group
Table 1 Demographic And Baseline Characteristics Of Patients In The ATHENA Study
Cumulative Oliceridine Dose (mg)*Group ALL
≤4
n=156
>4 to 8
n=85
>8 to 16
n=121
>16 to 36
n=168
>36
n=238
N=768
Demographic Characteristics
Female,
n (%)
93 (59.6) 52 (61.2) 78 (64.5) 117 (69.6) 158 (66.4) 498 (64.8)
Mean (SD) age, years 51.6 (15.0) 52.9 (15.4) 53.3 (15.4) 54.8 (16.3) 56.0 (17.0) 54.1 (16.1)
Age group (years), n (%)
<65 124 (79.5) 62 (72.9) 88 (72.7) 108 (64.3) 139 (58.4) 521 (67.8)
≥65 to <75 23 (14.7) 17 (20.0) 20 (16.5) 46 (27.4) 79 (33.2) 185 (24.1)
≥75 9 (5.8) 6 (7.1) 13 (10.7) 14 (8.3) 20 (8.4) 62 (8.1)
Race, n (%)
Caucasian 120 (76.9) 70 (82.4) 95 (78.5) 133 (79.2) 178 (75.4) 596 (77.8)
African American 29 (18.6) 10 (11.8) 22 (18.2) 26 (15.5) 50 (21.2) 137 (17.9)
Asian 2 (1.3) 1 (1.2) 0 5 (3.0) 5 (2.1) 13 (1.7)
Other 5 (3.2) 4 (4.8) 4 (3.3) 4 (2.4) 5** (2.0) 22 (2.9)
Clinical Characteristics
Mean (SD) BMI, kg/m2 30.1 (7.2) 29.9 (6.8) 30.6 (6.9) 30.8 (6.8) 30.8 (8.2) 30.5 (7.4)
BMI group (kg/m2), n (%)
<30 90 (57.5) 51 (60.0) 63 (52.1) 86 (51.2) 126 (52.9) 416 (54.2)
≥30 66 (42.3) 34 (40.0) 58 (47.9) 82 (48.8) 112 (47.1) 352 (45.8)
Mean (SD) pain score at baseline† 6.1 (1.8) 6.0 (2.0) 6.3 (2.1) 6.2 (2.0) 6.5 (2.4) 6.3 (2.1)
MRPSS, none to minimal sedation, n (%) 68 (45.9) 29 (35.8) 37 (33.6) 78 (48.8) 120 (54.8) 332 (46.2)
Notes: *The morphine milligram equivalent (MME) of oliceridine to morphine is approximately 5:1. †Patients self-rated pain on an 11-point NRS: 0 = no pain to 10 = worst
pain imaginable. **Missing information in 2 patients.
Abbreviations: BMI, body mass index; MPRSS, Moline-Roberts Pharmacologic Sedation Scale; NRS, numeric rating scale; SD, standard deviation.
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>65 to <75 years; 34% in those ≥75 years; vs 33% in the
overall population).
There were 46% of patients at baseline, 66% at 30
mins after oliceridine dosing, and 93% at the end of the
study that reported “none to minimal sedation” in the
MRPSS (Supplementary Table 3). Likewise, the AE of
somnolence (and sedation) reported by patients in all oli-
ceridine dose groups was minimal (Table 4).
The mean opioid withdrawal symptom score was low
(3.9) and comparable across groups (ranging from 3.3 to
4.1) (Supplementary Table 4). A total of 97% of patients
reported “none to mild” withdrawal symptoms (i.e.,
SOWS score <17), 3% reported moderate symptoms
(score ≥17 to ≤32), and less than 1% of patients reported
severe symptoms (score >32) (Supplementary Table 4).
Twenty patients had at least one hepatic laboratory
result, meeting “potentially clinically significant abnormal
liver function test” (PCSA LFT) criteria. One of these
patients experienced an SAE considered “possibly” related
to oliceridine by the investigator and previously described.
No patient experienced jaundice. Causality assessments
conducted by an independent panel of experts reported
that none of the LFT abnormalities were likely the result
of oliceridine treatment.
The incidence of respiratory AEs associated with vital
sign assessments is shown in Table 5. The percentage of
patients with an oxygen saturation <90% increased from the
lower to higher oliceridine cumulative dose groups (2–8%);
no clinically relevant sequelae were noted. For the respira-
tory AEs associated with vital sign assessments and typi-
cally considered opioid-related, there was no apparent dose-
effect noted across increasing oliceridine cumulative dose
groups. Only one of these (the SAE) was considered by the
investigator to be related to oliceridine (previously dis-
cussed) and no patients required the use of naloxone during
oliceridine treatment. No other clinically relevant abnorm-
alities were observed for vital signs. Likewise, there were
no other clinically meaningful laboratory or serum chemis-
try changes associated with oliceridine.
Changes from baseline in ECG parameters were mini-
mal and similar across cumulative oliceridine dose groups
over time. Twenty-two patients distributed across all
cumulative oliceridine dose groups met one or both pre-
defined QTcF criteria. Half of these patients had ≥1 poten-
tial confounding factor that may have prolonged the QT
interval (eg, electrolyte abnormalities, use of concomitant
vasopressin, levofloxacin, amitriptyline, amiodarone, aze-
lastine, or medical condition as in right bundle branch
block or left bundle branch block); none of these patients
had any AE or ECG assessment abnormalities suggestive
of ventricular extrasystoles, premature ventricular contrac-
tions, or ventricular tachycardia.
Effectiveness
The mean NRS pain score at baseline was 6.3 ± 2.1. The
mean change from baseline in the NRS pain score was
−2.2 ± 2.3 at 30 min after the first dose, indicating a rapid
reduction in pain intensity (Figure 4). The reductions were
comparable across cumulative oliceridine dose groups,
ranging from −2.8 to −1.9.
In patients with follow-up assessment available at their
end of treatment (n=225), the mean change from baseline in
NRS pain scores was −3.1 ± 3.1 across dose groups (ranging
from −3.5 to −2.8), indicating maintenance of pain reduction.
Discussion
The salient finding of this phase 3, multicenter, open-label
study was that oliceridine administered alone or as a
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Figure 2 Broad Surgical, Medical, and Emergency Department Patient Population.
Since the MedDRA hierarchy inadequately depicts the breadth of surgeries in the
ATHENA study, the “reasons for receiving oliceridine” were also grouped following
medical review. The most common reasons (>5%) for receiving oliceridine (by
procedure) were knee arthroplasty (127 patients [16.5%]), hysterectomy (72
patients [9.4%]), hip arthroplasty (58 patients [7.6%]), colectomy (54 patients
[7.0%]), and mammoplasty (46 patients [6.0%]). Medical conditions included: left
humerus fracture (2); radiculopathy (2); post-surgical capsulitis of right shoulder (1);
sickle-cell anemia (1); Crohn’s disease (1); post-laminectomy syndrome (1); lumbago
with sciatica (1); nephrolithiasis (1); and pain in left hip (1). Thirty-three patients
were from emergency settings (abdominal pain, n=1; acute back pain, n=6; shoulder
pain, n=1; flank pain, n=5; biliary colic, n=1; cervicalgia, n=1; crohn’s disease, n=1;
exacerbation of bilateral foot pain, n=1; pancreatitis, n=2; perianal abscess, n=1;
right-hand cellulitis, n=1; right hip dislocation, n=1; sickle-cell disease, n=3; motor
vehicle accident, n=3; spinal stenosis, n=1, systemic lupus erythematosus, n=1,
thrombosis of bypass graft, n=1, tooth abscess, n=1; urinary tract infection, n=1;
vertebral fracture, n=1).
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component of multimodal analgesia in adult patients hav-
ing moderate to severe pain with surgical procedures or
medical conditions was generally safe and well tolerated in
a broad-based population. The inclusion and exclusion
criteria used in the ATHENA trial were intentionally
designed to enroll a more clinically diverse population
with fewer protocol restrictions than typically included in
the setting of a randomized controlled clinical trial, reflect-
ing a study population and a setting, more directly general-
izable to real-world practice settings; particularly in the
post-surgical setting, as 94% of the study participants were
enrolled from this setting. The pattern, type, incidence and
severity of AEs did not differ from those observed in prior
randomized clinical trials.
Effectiveness
Oliceridine was associated with a potent analgesic effect
and a rapid onset of action (2.2-point reduction of pain
score within 30 mins) consistent with previous reports.11,12
For purposes of context, it is believed that the morphine
milligram equivalent (MME) of oliceridine when initiating
treatment is approximately 5:1 for the first dose (Data on
file). The rapid reduction in NRS pain score along with
sustained decreased pain intensity until the end of treat-
ment demonstrated the analgesic effectiveness of oliceri-
dine. Lack of efficacy leading to discontinuation was
reported in less than 5% of patients.
It is noteworthy that despite patients receiving local
anesthetics (76%), NSAIDs (69%); and oral opioids (48%)
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prior to the first dose of oliceridine, the average pain score
prior to oliceridine administration was 6.3, further support-
ing the need for potent analgesics including parenteral
opioids. The 84% rate of multimodal analgesia use in
ATHENA, particularly in the post-surgical setting, is simi-
lar to the findings reported from a recent study that
Table 2 Prior And Concomitant Medications
Cumulative Oliceridine Dose (mg)*Group All
≤4
n=156
>4 to 8
n=85
>8 to 16
n=121
>16 to 36
n=168
>36
n=238
N=768
Medications Used Prior to First dose of Oliceridine
Acetaminophen and non-opioid combination¶ 40 (25.6) 30 (35.3) 51 (42.1) 78 (46.4) 141 (59.2) 340 (44.3)
Alpha agonists (clonidine/ dexmedetomidine) 4 (2.6) 8 (9.4) 16 (13.2) 38 (22.6) 49 (20.6) 115 (15.0)
Gabapentin/Pregabalin 25 (16.0) 13 (15.3) 20 (16.5) 65 (38.7) 107 (45.0) 230 (29.9)
Ketamine 11 (7.1) 12 (14.1) 11 (9.1) 13 (7.7) 11 (4.6) 58 (7.6)
Local anesthetics 106 (67.9) 65 (76.5) 105 (86.8) 133 (79.2) 177 (74.4) 586 (76.3)
NSAIDs-nonselective 65 (41.7) 27 (31.8) 56 (46.3) 91 (54.2) 117 (49.2) 356 (46.4)
NSAID-selective 9 (5.8) 12 (14.1) 17 (4.0) 45 (26.8) 87 (36.6) 170 (22.1)
Opioid anesthetics (mainly fentanyl) 115 (73.7) 73 (85.9) 110 (90.9) 143 (85.1) 207 (87.0) 648 (84.4)
Oral opioids 81 (51.9) 48 (56.5) 70 (57.9) 79 (47.0) 93 (39.1) 371 (48.3)
Steroids 89 (57.1) 53 (62.4) 74 (61.2) 88 (52.4) 106 (44.5) 410 (53.4)
Concomitant Medications Used After the First dose of Oliceridine
Subjects with ≥1 analgesic 101 (64.7) 63 (74.1) 106 (87.6) 155 (92.2) 223 (93.7) 648 (84.4)
Acetaminophen and non-opioid combination¶ 46 (29.5) 33 (38.8) 57 (47.1) 85 (50.6) 161 (67.6) 382 (49.7)
Gabapentin/Pregabalin 19 (12.2) 9 (10.6) 19 (15.7) 35 (20.8) 68 (28.6) 150 (19.5)
NSAID- nonselective 66 (42.3) 43 (50.6) 76 (62.8) 109 (64.9) 137 (57.6) 431 (56.1)
NSAID- selective 2 (1.3) 2 (2.4) 5 (4.1) 15 (8.9) 36 (15.1) 60 (7.8)
Steroids 9 (5.8) 8 (9.4) 11 (9.1) 15 (8.9) 15 (6.3) 58 (7.6)
Opioids administered after last dose of oliceridine
Oral Opioids 121 (77.6) 71 (83.5) 101 (83.5) 126 (75.0) 180 (75.6) 599 (78.0)
Notes: *The morphine milligram equivalent (MME) of Oliceridine to Morphine is approximately 5:1. Local anesthetics used prior to the first dose of Oliceridine included
mainly Bupivacaine, Lidocaine, Marcaine, Ropivacaine and those used concomitantly with Oliceridine were: Bupivacaine, Lidocaine, Marcaine and Octacaine. ¶Combination
with acetaminophen include aspirin, diphenhydramine, chlorpheniramine, caffeine.
Table 3 Exposure To Oliceridine
Cumulative Oliceridine Dose (mg)*Group ALL
≤4
n=156
>4 to 8
n=85
>8 to 16
n=121
>16 to 36
n=168
>36
n=238
N=768
Method of administration, n (%)
Bolus 148 (94.9) 66 (77.6) 71 (58.7) 70 (41.7) 65 (27.3) 420 (54.7)
PCA 8 (5.1) 19 (22.4) 50 (41.3) 98 (58.3) 173 (72.7) 348 (45.3)
Duration of exposure, hours
Mean (SD) 1.5 (3.6) 10.5 (12.3) 19.2 (16.8) 35.9 (20.5) 53.7 (22.9) 28.7 (26.9)
Median (min, max) 0.2 (0, 26.8) 4.5 (0.3, 51.7) 16.4 (0.2, 73.9) 36.3 (0.6, 93.1) 52.3 (6, 142.7) 20.3 (0, 142.7)
Cumulative oliceridine dose, mg
Mean (SD) 2.5 (1.0) 6.2 (1.2) 12.3 (2.3) 25.7 (5.5) 67.5 (28.6) 29.7 (31.1)
Median (min, max) 3.0 (0.9, 4.0) 6.0 (4.5, 8.0) 12.0 (8.5, 16.0) 25.5 (17.0, 36.0) 59.0 (36.5, 223.5) 19.3 (0.9, 223.5)
Notes: * The morphine milligram equivalent (MME) of oliceridine to morphine is approximately 5:1. “0” refers to single oliceridine dose exposure.
Abbreviations: max, maximum; min, minimum; PCA, patient-controlled analgesia; SD, standard deviation.
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evaluated the utilization patterns of multimodal pain man-
agement in joint arthroplasty recipients in the United
States, wherein 86% of patients received multimodal
analgesia.18
Safety
Oliceridine demonstrated a favorable safety and tolerabil-
ity profile, notably in patients at risk for opioid-related
complications. AEs were experienced by 64% of patients.
Nausea, constipation, and vomiting were documented in
31%, 11% and 10% of the patients, respectively. For
those considered “probably” or “possibly” related to oli-
ceridine, the reported incidence was lower for nausea
(18%), vomiting (7%), and constipation (6%). The rates
of serious SAEs and AEs leading to discontinuation were
low, and no deaths were reported in the study. There was
one SAE of respiratory depression which resolved, and
most of the patients experienced “none to minimal”
Table 4 Overall Summary Of AEs (Safety Analysis population)
Parameter Cumulative Oliceridine Dose (mg)*Group All
Patients
≤4
n=156
n (%)
>4 to 8
n=85
n (%)
>8 to 16
n=121
n (%)
>16 to 36
n=168
n (%)
>36
n=238
n (%)
N=768
n (%)
Patients with at least one AE 60 (38.5) 52 (61.2) 79 (65.3) 125 (74.4) 174 (73.1) 490 (63.8)
Patients with at least one SAE 1 (0.6) 4 (4.7) 5 (4.1) 7 (4.2) 9 (3.8) 26 (3.4)
Patients with at least one AE leading to early study
medication discontinuation
5 (3.2) 1 (1.2) 3 (2.5) 7 (4.2) 1 (0.4) 17 (2.2)
Possibly or probably related to study drug 32 (20.5) 27 (31.8) 47 (38.8) 68 (40.5) 82 (34.5) 256 (33.3)
AEs by maximum intensity
Mild 44 (28.2) 37 (43.5) 45 (37.2) 66 (39.3) 95 (39.9) 287 (37.4)
Moderate 14 (9.0) 12 (14.1) 29 (24.0) 56 (33.3) 77 (32.4) 188 (24.5)
Severe 2 (1.3) 3 (3.5) 5 (4.1) 3 (1.8) 2 (0.8) 15 (2.0)
Most Common AEs (≥5% of Patients in any Cumulative Dose Group)
Nausea 17 (10.9) 22 (25.9) 41 (33.9) 63 (37.5) 96 (40.3) 239 (31.1)
Constipation 3 (1.9) 5 (5.9) 19 (15.7) 25 (14.9) 32 (13.4) 84 (10.9)
Vomiting 5 (3.2) 4 (4.7) 11 (9.1) 17 (10.1) 43 (18.1) 80 (10.4)
Pruritus 1 (0.6) 4 (4.7) 9 (7.4) 7 (4.2) 17 (7.1) 38 (4.9)
Hypokalemia 2 (1.3) 2 (2.4) 2 (1.7) 6 (3.6) 24 (10.1) 36 (4.7)
Dizziness 3 (1.9) 5 (5.9) 8 (6.6) 8 (4.8) 10 (4.2) 34 (4.4)
Headache 3 (1.9) 3 (3.5) 6 (5.0) 8 (4.8) 14 (5.9) 34 (4.4)
Hypotension 4 (2.6) 1 (1.2) 5 (4.1) 9 (5.4) 9 (3.8) 28 (3.6)
Insomnia 1 (0.6) 2 (2.4) 5 (4.1) 12 (7.1) 8 (3.4) 28 (3.6)
Pyrexia 2 (1.3) 0 5 (4.1) 9 (5.4) 9 (3.8) 25 (3.3)
Hypocalcemia 1 (0.6) 1 (1.2) 2 (1.7) 5 (3.0) 15 (6.3) 24 (3.1)
Hypophosphatemia 0 2 (2.4) 1 (0.8) 7 (4.2) 13 (5.5) 23 (3.0)
Procedural Nausea 7 (4.5) 6 (7.1) 4 (3.3) 2 (1.2) 2 (0.8) 21 (2.7)
Flatulence 1 (0.6) 2 (2.4) 10 (8.3) 6 (3.6) 1 (0.4) 20 (2.6)
Other AEs of interest
Somnolence 1 (0.6) 1 (1.2) 1 (0.8) 0 3 (1.3) 6 (0.8)
Sedation 0 1 (1.2) 0 4 (2.4) 3 (1.3) 8 (1.0)
Notes: *The morphine milligram equivalent (MME) of oliceridine to morphine is approximately 5:1. AEs reported are those occurring during treatment with oliceridine and
post-treatment follow-up; or any pre-existing AEs that have worsened in severity during the treatment phase and post-treatment follow-up. Percentages were based on the
number of patients in each cumulative dose group. All AEs were coded using MedDRA Version 19.0.
Abbreviations: AE, adverse event; SAE, serious adverse event.
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sedation/somnolence. The protocol allowed the use of
antiemetics as prophylaxis. Thus, the incidence of nausea
and vomiting related specifically to oliceridine alone is
difficult to interpret.
A recently conducted retrospective analysis from a large
healthcare system including 21 acute care hospitals and
135,379 patients undergoing surgical and endoscopic proce-
dures and receiving conventional opioids reported at least one
AE in 73% of patients.19 This retrospective analysis found that
opioid-related AEs were associated with increased inpatient
mortality (odds ratio [OR], 28.8; 95% CI, 24.0–34.5), pro-
longed length of stay (OR, 3.1; 95% CI, 2.8–3.4), high cost of
hospitalization (OR, 2.7; 95% CI, 2.4–3.0), and higher rate of
30-day readmission (OR, 1.3; 95% CI, 1.2–1.4).19 In the
ATHENA trial, AEs were reported in 64% of patients and no
deaths were reported. ATHENA did not investigate the length
of stay, 30-day readmission or cost of hospitalization.
Opioid-induced nausea and vomiting is one of the main
causes of PONV20 with a reported incidence of 30%
vomiting, and nausea ranging from 50 to as high as 80%
in high-risk patients.21 Although a non-life-threatening
side effect, PONV can have a substantial impact on patient
outcomes, including quality of life.22 Thus, the findings of
the low rates of nausea and vomiting associated with
oliceridine in this trial are important in the context of
strategies for the management of postoperative nausea
and vomiting to enable earlier mobilization and discharge.
Opioid-induced respiratory depression (OIRD), a poten-
tially fatal complication associated with conventional opioids
in the acute setting involves complex and inter-related
factors.23 Depending on the type of surrogate measures
used the rates varied, for eg, with naloxone utilization as a
surrogate, the incidence of respiratory depression was 1.9–
2.0%, while using oxygen saturation <90% or <85% as
surrogate resulted in incidences as high as 22%.24 In one
meta-analysis, 1.2% to 11.5% of patients receiving parenteral
opioids via a PCA device after major surgery had respiratory
Table 5 Incidence Of Respiratory AEs And Associated Vital Signs
Parameter Cumulative Oliceridine Dose (mg), Group All Patients
≤4
n=156
n (%)
>4 to 8
n=85
n (%)
>8 to 16
n=121
n (%)
>16 to 36
n=168
n (%)
>36 mg
n=238
n (%)
N=768
n (%)
AEs (based on MedDRA terms)*
Hypoxia 0 3 (3.5) 3 (2.5) 8 (4.8) 3 (1.3) 17 (2.2)
Dyspnea 0 1 (1.2) 2 (1.7) 2 (1.2) 3 (1.3) 8 (1.0)
Bradypnea 1 (0.6) 0 0 0 1 (0.4) 2 (0.3)
Respiratory failure¶ 0 0 0 1 (0.6) 0 1 (0.1)
Tachypnea 1 (0.6) 0 0 0 0 1 (0.1)
Respiratory depressionŦ 1 (0.6) 0 0 0 0 1 (0.1)
Respiratory acidosis** 0 0 0 0 1 (0.4) 1 (0.1)
Associated significant Vital Signs
Oxygen saturation < 90%a 3 (1.9) 2 (2.4) 5 (4.1) 14 (8.3) 18 (7.6) 42 (5.5)
Notes: *Investigators used their clinical judgement. ¶Began approximately 4 days after the completion of oliceridine administration (nonserious, moderate, not related)
resolved in approximately 2 days. Patients experienced shortness of breath and exacerbation of COPD. ŦRespiratory depression was defined as a respiratory rate <8 bpm.
**Nonserious, mild, not related; resolved in approximately 14 hrs. Patient continued to receive oliceridine treatment. aNo clinically relevant sequelae were noted.
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depression.24 Using the Anesthesia Closed Claims Project
database of 9,799 claims, OIRD was “probably”, “possibly”,
or “definitely” reported in 92 claims, and more than half of
these claims were associated with death.25 In addition to the
clinical consequences, the occurrence of OIRD in patients
undergoing major surgical procedures has been shown to
significantly increase total inpatient costs, patient in-hospital
length of stay, and readmission rates.1 To reduce the risk of
respiratory events, clinicians may limit opioid dosing, poten-
tially resulting in inadequate analgesia.26 In the ATHENA
study, oxygen saturation <90% was reported in 6% and none
of the patients required naloxone. These findings support the
early phase 3 trials which compared oliceridine with mor-
phine in treating acute pain after bunionectomy or
abdominoplasty.11,12 In both these studies, oliceridine was
associated with potentially improved respiratory safety
profile.11,12 Together, the findings of the low incidence of
respiratory depression are consistent with the selective nature
of oliceridine on the G-protein effector pathway.
In marked contrasts to conventional opioids,27–29 the
incidence of AEs/SAEs leading to early discontinuation in
this study was similar in the elderly (aged >65 years of
age) and obese subgroups (BMI ≥30 kg/m2) when com-
pared with the overall population.
A few patients in the ATHENA study experienced QT
prolongation, but there were no instances of ventricular
arrhythmias. Previous studies of oliceridine in healthy
volunteers in a thorough QT (tQT) study found no evi-
dence of any clinically significant effect at the highest
proposed clinical dose of 3 mg on cardiac repolarization
(Data on file). However, at the supratherapeutic dose of 6
mg, a minor, transient effect, with the upper one-sided
95% confidence limit of the mean placebo-adjusted change
from baseline in QTcF exceeded the 10 msec, at 2.5 mins,
1 hr, and 2 hrs post-dose (Data on file). Subsequently, in
the randomized clinical trials of oliceridine, there was no
evidence of QT prolongation.11,12 A recent study of about
500 non-cardiac surgery patients reported QT prolongation
as a common occurrence, and perioperative medication,
including anesthetics (isoflurane), analgesics (ketorolac
and methadone), and antibiotics, was one of the causative
factors.30 Unlike the phase 3 controlled clinical trials of
oliceridine, the study design of ATHENA did not have any
restrictions on the use of prior or concomitant medications,
and indeed in half of the reported cases, patients received
medications known to cause QT prolongation. Thus, the
results could be confounded by the cumulative effect of
several drugs likely contributing to the postoperative QTc
interval prolongation. Further tQT evaluation is underway.
There are several limitations to the ATHENA study.
First, the open-label design can introduce bias in the find-
ings of the study. Secondly, most patients received local
anesthetics, NSAIDs, and/or other opioids prior to the first
dose of oliceridine. The non-opioid multimodal analgesics
were also allowed as part of the standard of care. The
influence of the prior medications, including opioids and
concomitant non-opioid analgesics contributing to the
adverse events cannot be ruled out. In addition, although
the protocol defined that no concomitant opioids could be
administered during oliceridine treatment, several patients
received opioids after the last dose of oliceridine. This
could have further contributed to the AEs observed in
the study. Lastly, the lack of a control group limits the
true estimation of the AEs.
Conclusion
The ATHENA trial was intended to assess the safety of
oliceridine in a broad-based group of adult patients experi-
encing moderate to severe pain following surgical proce-
dures or non-surgical medical conditions. Although the
study was not powered for safety or efficacy, oliceridine
IV was generally safe and well tolerated in this heteroge-
neous population of patients with moderate to severe acute
pain for whom a parenteral opioid was warranted. Most of
the patients enrolled in the ATHENA trial received olicer-
idine for the management of moderate to severe post-surgi-
cal acute pain. Thus, the findings in the patients with non-
surgical medical conditions are limited to the patients char-
acterized in this study and not generalizable to larger non-
surgical populations. The low incidence of respiratory AEs,
and PONV, along with rapid and sustained analgesia
allowed for titration to a dose that provided analgesia and
favorable tolerability. Oliceridine, a novel centrally acting
G-protein pathway-selective µ-opioid receptor agonist may
represent a potential new treatment option for patients
requiring IV opioid therapy.
Data Availability
Data from the ATHENA trial are held by Trevena Inc. and
are not publicly available. Access to specific data sets,
protocols, and reports will be considered on the basis of
proposed quality and alignment with the aims of the ori-
ginal study.
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